Orion (ORNBV) Q2 2025 earnings summary

Executive summary

• All divisions delivered strong performance in Q2 and H1 2025, with significant growth in innovative medicines, especially NubeqaⓇ, and robust results across branded products, generics, and animal health.

• Achieved key regulatory milestones, including FDA approval and CHMP recommendation for darolutamide in combination with ADT for metastatic hormone-sensitive prostate cancer.

• Expanded research pipeline with new biologics expected to enter clinical stage within 12–24 months and new licensing agreements for cancer and Parkinson’s disease treatments.

• Major R&D and business developments include a new Cambridge R&D center, expanded clinical trials, and leadership changes in key divisions.

• EasyhalerⓇ peak sales potential upgraded to over EUR 300 million annually.

Financial highlights

• Q2 2025 net sales rose 27% year-over-year to EUR 416.5 million; operating profit up 59% to EUR 104.6 million; operating margin at 25.1%.

• H1 2025 net sales increased 21.1% to EUR 771.0 million; operating profit up 49.8% to EUR 182.5 million; H1 margin at 23.7%.

• Q2 operating cash flow per share was EUR 0.57 (+189.7%); H1 at EUR 1.12 (+14.1%).

• Royalties, especially from NubeqaⓇ, contributed almost EUR 46 million to operating profit.

• H1 2025 profit for the period was EUR 143.8 million (+50.2%); basic EPS at EUR 1.02 (+50.0%).

Outlook and guidance

• 2025 net sales expected between EUR 1,630–1,730 million; operating profit guidance set at EUR 400–500 million.

• Guidance range remains wide due to uncertainties in NubeqaⓇ royalties, timing of R&D expenses, and market dynamics.

• R&D expenses expected to rise in H2 as projects progress; capital expenditure to remain at 2024 levels.

• Outlook excludes potential milestone payments and acquisitions.